Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Comment by toothpickon Nov 01, 2010 5:05pm
270 Views
Post# 17641683

RE: Final shakeout before News - YES !

RE: Final shakeout before News - YES !
It could be any time now !

This is my transcript of the Q2 CC - July 30 - (https://www.stockhouse.com/Bullboards/MessageDetailThread.aspx?p=28456146&m=28457799&r=0&s=BNC&t=LIST )


"This may not be a perfect transcript but its about that:

"...we are preparing to initiate a launch study with Urocidin in the second half that could become the ??? study of this very interresting product to treat bladder cancer

Urocidin is anovel treatment for refractory bladder cancer which represents the kind of innovative solution we want
to offer to urologist and their patients

As stated earlier we are committed to bladder cancer as an area of therapy to focus as we look to enhance
the range of solutions we can offer to urologist

We carry evaluating data of the first phase III of Uropcidin and expect to finish analysis this quarter prior
to initiating the second phase III study."

"

--> Q3 ended with September






Bullboard Posts